Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity.
Adhireksan Z, Davey GE, Campomanes P, Groessl M, Clavel CM, Yu H, Nazarov AA, Yeo CH, Ang WH, Dröge P, Rothlisberger U, Dyson PJ, Davey CA.
Adhireksan Z, et al. Among authors: davey ge, davey ca.
Nat Commun. 2014 Mar 18;5:3462. doi: 10.1038/ncomms4462.
Nat Commun. 2014.
PMID: 24637564
Free PMC article.